rss
J Clin Pathol 2008;61:307-310 doi:10.1136/jcp.2007.049460
  • Original article

EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder

  1. A Brunner1,
  2. M Prelog2,
  3. I Verdorfer1,
  4. A Tzankov3,
  5. G Mikuz1,
  6. C Ensinger1
  1. 1
    Institute of Pathology, Medical University of Innsbruck, Austria
  2. 2
    Department of Pediatrics, Medical University of Innsbruck, Austria
  3. 3
    Institute of Pathology, University of Basel, Switzerland
  1. Dr Andrea Brunner, Institute of Pathology, Medical University of Innsbruck, Muellerstrasse 44, Innsbruck, Austria; andrea.brunner{at}i-med.ac.at
  • Accepted 22 May 2007
  • Published Online First 22 June 2007

Abstract

Background: EpCAM is an adhesion molecule of the basolateral membranes in a variety of epithelial cells. Over-expression has been detected in many epithelial tumours and has been associated with high stage, high grade and a worse survival in some tumour types.

Aims: To assess the prognostic value of EpCAM in urothelial carcinoma of the bladder.

Methods: EpCAM expression was analysed by immunohistochemistry using a monoclonal antibody (clone VU-1D9) on a tissue microarray comprising 99 urothelial carcinomas of the bladder diagnosed between 1994 and 1997.

Results: A significant relationship between high grade, advanced stage, and EpCAM expression was found, and expression of EpCAM was associated with a worse overall survival when compared to EpCAM negative tumours (p = 0.033). Multivariate analysis showed that EpCAM expression was not an independent prognostic factor for overall survival in urothelial carcinoma of the bladder.

Conclusion: EpCAM expression is associated with advanced stage, high grade and poor overall survival in urothelial carcinoma of the bladder, but lacks an independent prognostic significance. The strong association with high grade tumours suggests a possible role during tumour progression and makes EpCAM a potential target for antibody mediated therapy.

Footnotes

  • Competing interests: None.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. jcp.2007.049460v1
    2. 61/3/307 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content


Free trial
Individuals may register for a free 60 day online trial to all content.

Free archive
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they ar